BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37418931)

  • 1. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.
    Ammitzbøll C; Dyrby TB; Börnsen L; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Lundell H; Jensen PEH; Sørensen PS; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2023 Sep; 77():104854. PubMed ID: 37418931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI.
    Saraste M; Bezukladova S; Matilainen M; Sucksdorff M; Kuhle J; Leppert D; Airas L
    Mult Scler Relat Disord; 2021 May; 50():102810. PubMed ID: 33556656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
    Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
    Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
    Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
    Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
    Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
    Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
    Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum neurofilament associates with diffuse white matter damage in MS.
    Saraste M; Bezukladova S; Matilainen M; Tuisku J; Rissanen E; Sucksdorff M; Laaksonen S; Vuorimaa A; Kuhle J; Leppert D; Airas L
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33293460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
    Preziosa P; Pagani E; Meani A; Marchesi O; Conti L; Falini A; Rocca MA; Filippi M
    J Neurol; 2023 Feb; 270(2):810-823. PubMed ID: 36201016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disability in progressive MS is associated with T2 lesion changes.
    Ammitzbøll C; Dyrby TB; Lyksborg M; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Garde E; Sørensen PS; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2018 Feb; 20():73-77. PubMed ID: 29324249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
    Abdelhak A; Antweiler K; Kowarik MC; Senel M; Havla J; Zettl UK; Kleiter I; Skripuletz T; Haarmann A; Stahmann A; Huss A; Gingele S; Krumbholz M; Benkert P; Kuhle J; Friede T; Ludolph AC; Ziemann U; Kümpfel T; Tumani H
    Ann Clin Transl Neurol; 2024 Feb; 11(2):477-485. PubMed ID: 38111972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
    Lee HL; Seok JM; Chung YH; Min JH; Baek SH; Kim SM; Sohn E; Kim J; Kang SY; Hong YH; Shin HY; Cho JY; Oh J; Lee SS; Kim S; Kim SH; Kim HJ; Kim BJ; Kim BJ
    Mult Scler Relat Disord; 2023 Nov; 79():104957. PubMed ID: 37688927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-acute blood biomarkers and disease progression in traumatic brain injury.
    Newcombe VFJ; Ashton NJ; Posti JP; Glocker B; Manktelow A; Chatfield DA; Winzeck S; Needham E; Correia MM; Williams GB; Simrén J; Takala RSK; Katila AJ; Maanpää HR; Tallus J; Frantzén J; Blennow K; Tenovuo O; Zetterberg H; Menon DK
    Brain; 2022 Jun; 145(6):2064-2076. PubMed ID: 35377407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
    Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
    Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging.
    Shi Z; Pan Y; Yan Z; Ding S; Hu H; Wei Y; Luo D; Xu Y; Zhu Q; Li Y
    Mult Scler Relat Disord; 2023 Mar; 71():104572. PubMed ID: 36821979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity.
    Ayrignac X; Le Bars E; Duflos C; Hirtz C; Maleska Maceski A; Carra-Dallière C; Charif M; Pinna F; Prin P; Menjot de Champfleur N; Deverdun J; Kober T; Marechal B; Fartaria MJ; Corredor Jerez R; Labauge P; Lehmann S
    Sci Rep; 2020 Jul; 10(1):10923. PubMed ID: 32616916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI.
    Shahim P; Politis A; van der Merwe A; Moore B; Ekanayake V; Lippa SM; Chou YY; Pham DL; Butman JA; Diaz-Arrastia R; Zetterberg H; Blennow K; Gill JM; Brody DL; Chan L
    Neurology; 2020 Aug; 95(6):e623-e636. PubMed ID: 32641529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.